[Economic evaluation of treatment on breast cancer].
College of Life Science, Ritsumeikan University.
Takeru
T
Shiroiwa
D061067:Antibodies, Monoclonal, Humanized / Q000191:economics; D000970:Antineoplastic Agents / Q000191:economics*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000191:economics; D003365:Costs and Cost Analysis; D004958:Estradiol / Q000031:analogs & derivatives / Q000191:economics; D005260:Female; D000077267:Fulvestrant; D005663:Furans / Q000191:economics; D006801:Humans; D007659:Ketones / Q000191:economics; D000068878:Trastuzumab; D000095662:Polyether Polyketides
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D004958:Estradiol; D000077267:Fulvestrant; D005663:Furans; D007659:Ketones; D000068878:Trastuzumab; C490954:eribulin; D000095662:Polyether Polyketides